Latest News about SRPT
Recent news which mentions SRPT
A Closer Look at 14 Analyst Recommendations For Sarepta Therapeutics
January 10, 2024
Tickers
SRPT
From Benzinga
Stocks Flip To Losses, Nvidia Defies Gravity, Bitcoin Pauses For A Breather: What's Driving Markets Tuesday?
January 09, 2024
From Benzinga
Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year
January 09, 2024
From Benzinga
Bumble (BMBL) Stock Pops as Elliott Builds a Stake in Rival Match
January 09, 2024
From InvestorPlace
Why Is Sarepta Therapeutics (SRPT) Stock Up Today?
January 09, 2024
From InvestorPlace
Acuity Brands Posts Upbeat Earnings, Joins Accolade, Urban Outfitters And Other Big Stocks Moving Higher On Tuesday
January 09, 2024
From Benzinga
2 Growth Stocks That Could Make You Richer in 2024 and Beyond
January 09, 2024
From Motley Fool
5 Biotech Stocks That Should Be On Investors' Radar As JPMorgan Healthcare Conference Gets Underway Monday
January 08, 2024
From Benzinga
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
From Benzinga
3 Things About Sarepta Therapeutics Every Smart Investor Knows
December 28, 2023
Tickers
SRPT
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
December 27, 2023
From Benzinga
Could Sarepta Therapeutics Be the Next Vertex Pharmaceuticals Stock?
December 22, 2023
From Motley Fool
1 Revolutionary Stock That Could Make You Richer in 2024 and Beyond
December 17, 2023
Tickers
SRPT
From Motley Fool
Could Sarepta Therapeutics Stock Help You Become a Millionaire?
December 09, 2023
Tickers
SRPT
From Motley Fool
My Take: 4 Strong Growth Stocks to Buy This Week
December 08, 2023
From Motley Fool
3 Monster Stocks in the Making
November 18, 2023
From Motley Fool
3 Stocks You’ll Regret Not Buying Soon: November 2023
November 16, 2023
From InvestorPlace
Catalent's Q1 Performance Beat Expectations: Analyst Says Main Focus On Manufacturing Outlook For Sarepta's Gene Therapy
November 15, 2023
From Benzinga
Jim Cramer Likes Founder Of AI Company, But Stock Is 'Losing A Fortune' And There's 'Too Much Hype There'
November 15, 2023
From Benzinga
1 Gene Therapy Stock to Buy and Hold for the Long Haul
November 08, 2023
Tickers
SRPT
From Motley Fool
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?
November 08, 2023
From Motley Fool
8 Health Care Stocks Whale Activity In Today's Session
November 07, 2023
From Benzinga
Sarepta Therapeutics (SRPT) Q3 2023 Earnings Call Transcript
November 02, 2023
Tickers
SRPT
From Motley Fool
Earnings Scheduled For November 1, 2023
November 01, 2023
From Benzinga
From Benzinga
Uphill Battle Ahead For Gene Therapy Player Sarepta, Analysts Lower Price Targets Following Duchenne Trial Miss
October 31, 2023
Tickers
SRPT
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.